These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 20225766)

  • 1. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
    Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
    Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
    Sing AP; Ambinder RF; Hong DJ; Jensen M; Batten W; Petersdorf E; Greenberg PD
    Blood; 1997 Mar; 89(6):1978-86. PubMed ID: 9058719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
    Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
    Paludan C; Münz C
    Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion.
    Ohshima K; Muta K; Nakashima M; Haraoka S; Tutiya T; Suzumiya J; Kawasaki C; Watanabe T; Kikuchi M
    Int J Cancer; 2001 Jul; 93(1):91-6. PubMed ID: 11391627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
    J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease.
    Oudejans JJ; Jiwa NM; Kummer JA; Horstman A; Vos W; Baak JP; Kluin PM; van der Valk P; Walboomers JM; Meijer CJ
    Blood; 1996 May; 87(9):3844-51. PubMed ID: 8611711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
    Angelini DF; Serafini B; Piras E; Severa M; Coccia EM; Rosicarelli B; Ruggieri S; Gasperini C; Buttari F; Centonze D; Mechelli R; Salvetti M; Borsellino G; Aloisi F; Battistini L
    PLoS Pathog; 2013; 9(4):e1003220. PubMed ID: 23592979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexpression of major histocompatibility complex class I and LMP1 in Epstein-Barr virus-positive Hodgkin's lymphoma in a pediatric age group.
    Aybar A; Krause JR
    Microsc Res Tech; 2005 Nov; 68(3-4):247-9. PubMed ID: 16276512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency.
    Kanavaros P; Jiwa M; van der Valk P; Walboomers J; Horstman A; Meijer CJ
    Hum Pathol; 1993 Jul; 24(7):725-9. PubMed ID: 8100553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
    Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
    Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.